BRITI: Formalizing Instruction in Trial-Related Imaging



By Deborah Borfitz

August 4, 2008 | Up till now, there has been no standardized training program for professionals who work with medical images in clinical trials. As industry groups such as Metrics Champion Consortium and Pharmaceutical Research and Manufacturers of America discuss the influence of training on blinded reader performance, they might want to pay attention to how a pair of Pennsylvania radiologists is tackling the issue.

Medical imaging experts Kohkan Shamsi, MD, PhD, and Richard Patt, MD, have just launched the Blinded Reader and Investigator Training Institute (BRITI) to facilitate the training of clinical trial personnel on a diversity of topics ranging from responsibilities of imaging investigators to properly measuring a tumor’s response to drugs, says Patt.

Each training module is followed by an examination. BRITI tracks training parameters on each participant and provides certification of completion of specific curricula.

The training is expected to be done primarily online via pre-recorded, audiovisual presentations where users control the learning pace, Patt says. But online training programs can be customized to include a real-time question-and-answer session. Live, on-site training is also available.

 Richard Patt 
Richard Patt
BRITI was initially created to train blinded readers who work for RadMD, another company started by Shamsi and Patt. As training was getting under way for those doctors earlier this year, Patt says, inquiries began pouring in from sponsors and clinical research organizations about training their clinical trial personnel.

Interpreting images in a medical clinic is considerably different than doing so for a clinical trial, which is guided by specific measurement criteria and “doesn’t look at [everything] that may be abnormal in patients, like kidney stones in patients in an oncology trial,” says Patt. Most radiologists haven’t learned the difference between a Phase II and Phase IV trial, let alone how to quantify drug efficacy via imaging studies.

Imaging investigators generally get only trial-specific training about the mechanics of image acquisition, continues Patt, but also need to understand basic regulatory issues and measurement criteria in order to better understand their role and responsibilities.

BRITI’s core curriculum covers how imaging is used in clinical trials and is useful for training physicians and other investigative site personnel as well as clinical research associates, biostatisticians, and project managers, says Patt. The focus of the more advanced training modules depends on the trial type and disease process. It will appeal primarily to blinded readers and clinical panel evaluators, as well as site personnel responsible for completing imaging portions of case report forms. “The vast majority of imaging today is on the oncology side, so [in addition to the primer courses], those modules will be most heavily used.”

The information in the modules exists in a variety of locations, says Patt. BRITI pulls it all into one convenient place. Patt and Shamsi, who each have more than 15 years of experience in medical imaging clinical development, oversee content along with selected experts on specific topics.

For now, BRITI modules are accessible only to groups on a negotiated per-use basis, says Patt. Pricing is based largely on training needs and size of the group. Over the next year, BRITI will also train at least 200 of the 500 independent radiologists that RadMD contracts with across the globe.

________________________________ 

This story first appeared in eCliniqua,one of Bio-IT World’s free e-newsletters. Subscribe here.

 

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .